Shilpa Medicare Limited — PPTs, 10-02-2025: Investor Presentation

**Financial Highlights:**

Shilpa Medicare reported total revenue of INR 320 crores for Q3 FY25, marking an 11% YoY increase. Gross profit improved to INR 229 crores with a gross margin of 72%, up from 67% in the previous year. EBITDA rose to INR 82 crores, an increase of 20% YoY, with an EBITDA margin of 26%. Profit After Tax (PAT) reached INR 32 crores, reflecting a substantial growth of 588% YoY.

**Strategic Initiatives and Growth Drivers:**

The company launched Nilotinib in the EU as a sole generic and initiated Phase III trials for Aflibercept. Shilpa Medicare continues to focus on enhancing its API business and securing timely approvals for filed products.

**Business Developments:**

In 9M FY25, total revenue was reported at INR 971 crores, a 12% growth YoY. The API division noted muted growth due to variable client buying patterns, yet ongoing capacity expansions are expected to drive growth starting Q1 FY26.

**Market Position and Competitive Advantage:**

Shilpa Medicare benefits from a 35-year track record and multiple regulatory-approved facilities. Its focus on complex APIs and a diverse portfolio strengthens its competitive edge.

**Investor Implications:**

The upward trend in revenue and margin enhancements indicate a positive outlook for Shilpa Medicare, with potential growth from product launches and strategic initiatives in both domestic and international markets. Investors should monitor developments as the pipeline of new products advances and regulatory approvals progress.